Prophase Labs Inc Stock Price, News & Analysis

ProPhase Labs (NASDAQ: PRPH) announced a live webcast on July 21, 2022, at 11:30 a.m. EST, hosted by CEO Ted Karkus. The session will cover the latest developments within ProPhase and its subsidiaries, including ProPhase Diagnostics, which offers COVID-19 testing and other clinical services, and ProPhase Precision Medicine, focusing on genomics testing. Participants can register here.

ProPhase Labs, Inc. (NASDAQ: PRPH) has announced the formation of a new subsidiary, ProPhase BioPharma, Inc. (PBIO), to focus on drug licensing and development. The company has entered into a licensing agreement with Global BioLife, Inc. for its antiviral compounds, Equivir and Equivir G, which are designed to combat viral outbreaks. ProPhase will leverage its extensive distribution network to commercialize Equivir as an OTC supplement and pursue FDA approval for Equivir G as a prescription antiviral. Human clinical trials for Equivir are set to begin soon.

ProPhase Labs (NASDAQ: PRPH) is expanding its in-house clinical testing capabilities by partnering with healthcare diagnostics innovators. The company has procured state-of-the-art equipment and executed a new lease for additional space at its Garden City, NY headquarters. Plans are underway for a new genomics laboratory, featuring Next Generation Sequencing for Whole Genome Sequencing and genetic testing. CEO Ted Karkus highlighted the strategic importance of these expansions in providing tailored clinical diagnostics and enhancing genetic research capabilities.

ProPhase Labs (NASDAQ: PRPH) announced that CEO Ted Karkus will present at the H.C. Wainwright 2022 Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand on May 24, 2022 at 7:00 A.M. ET for registered attendees.

ProPhase Labs offers a range of diagnostics and genomics services, including CLIA lab services and COVID-19 testing. The company plans to expand its services to include traditional clinical and genomics testing, as well as enhance its consumer offerings in whole genome sequencing.

ProPhase Labs, Inc. (NASDAQ: PRPH) reported record net revenues of $47.5 million for Q1 2022, a 211% increase from Q1 2021. Net income soared to $12.5 million, or $0.81 per share, representing a remarkable 1082% year-over-year growth. The company declared a special cash dividend of $0.30 per share, payable on June 3, 2022. ProPhase performed 377,000 diagnostics tests, up from 113,000 tests in the same quarter last year. Cash and marketable securities totaled $29.4 million, supporting future expansions.

ProPhase Labs (NASDAQ: PRPH) announced that Chairman and CEO Ted Karkus will present at the Spring Into Action – Best Ideas Virtual Investor conference from May 17-20, 2022. Karkus is scheduled to speak on May 17 at 1:00 PM ET. The conference will include opportunities for one-on-one meetings with investors. ProPhase Labs focuses on diagnostics and genomics, offering services like COVID-19 testing and whole genome sequencing. Interested parties can register for the event and schedule meetings through the provided links.

ProPhase Labs, Inc. (Nasdaq: PRPH) has appointed Bill White as the new Chief Financial Officer, effective May 23, 2022. Mr. White brings over 30 years of experience, previously serving as CFO of Intellicheck, Inc. and co-founding FocusMicro, Inc., where he grew revenues to over $36 million in five years. He will replace Monica Brady, who will continue with the company in a different capacity. White has been awarded a stock option for 400,000 shares with an exercise price of $6.74 per share. This appointment is seen as a strategic move to enhance the company’s financial management and growth.

ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on May 13, 2022, at 11:00 a.m. ET to discuss first-quarter results for the period ending March 31, 2022. CEO Ted Karkus will lead the call, which will include a question-and-answer session. Participants can register via a provided link and will receive dial-in details upon registration. Toll-free dial-in is available at 1-866-777-2509 for U.S. callers, and international callers can use 1-412-317-5413. The conference call will be broadcast live and available for replay after it concludes.

ProPhase Labs, Inc. (NASDAQ: PRPH) announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on May 4, 2022, at 1:30 PM EST. The presentation will be accessible through a webcast link provided in the announcement.

ProPhase Labs focuses on diagnostics and genomics, offering services like whole genome sequencing and COVID-19 testing through its CLIA-certified laboratories. The company aims to expand its testing capabilities globally and continues to pursue strategic investments.